Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLR 131 + EBRT in Recurrent Head and Neck Cancer
NCT04105543Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Iopofosine I-131 in head and neck cancer (HNC), sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of Treatment Related Adverse Events up to 18 weeks and Summary of Adverse Events Possibly Related to Treatment up to 18 weeks. Started Dec 2019; status: completed.
02
Drugs
Iopofosine I-131
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04105543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105543.